We all know that the medications used to treat chronic pain from anti-depressants to anti-seizure medications have a long list of side effects and very little actual pain-reducing effects. Take fibromyalgia as a very good example with the three approved medications being Savella, Cymbalta, and Lyrica… however, when you look into it very few people get a positive result and that is not counting the side effects they put up with for that. So are they really all that effective when so few of the FM population even respond to them? Apparently good enough. Then there are the painkillers, which when it comes to chronic pain you might as well call pain dullers… for a short duration of time. Never a great solution and one with a massive stigma these days. We have all sorts of other alternative treatments but that is not what this is about. This is about Actual treatments… and one coming down the line that might actually do something. Color me intrigued.
“Activating A3 receptor with adenosine molecule prevented, reversed chronic pain
The researchers analyzed more than 300 rodent models of chronic neuropathic pain – pain that results from nerve damage.
They found that activating a receptor in the brain called A3 halted or reversed chronic pain in the rodents, and that this receptor could be activated by a small adenosine molecule and other small-molecule medication created by the National Institutes of Health.
What is more, activating the A3 receptor with a small adenosine molecule did not alter the normal pain threshold in rodents or trigger the reward center of the brain – a process that can lead to addiction with opioid use.
Commenting on their findings, Prof. Salvemini says:
“It has long been appreciated that harnessing the potent pain-killing effects of adenosine could provide a breakthrough step towards an effective treatment for chronic pain.
Our findings suggest that this goal may be achieved by focusing future work on the A3 adenosine receptor (A3AR) pathway, in particular, as its activation provides robust pain reduction across several types of pain.”
The team notes that A3AR agonists are already undergoing clinical trials for treatment of inflammation and cancer, and – as demonstrated in this study – the drugs have caused no serious side effects so far.
“These studies suggest that A3AR activation by highly selective small molecular weight A3AR agonists – such as MRS5698 – activates a pain-reducing pathway supporting the idea that we could develop A3AR agonists as possible new therapeutics to treat chronic pain,” adds Prof. Salvemini.”
‘Robust pain reduction across several pain types’. Now that is what I am talking about! No serious side effects so far, who knows what that means but let’s hope it isn’t the long lists we deal with now. I am fascinated by this idea anyway.